全文获取类型
收费全文 | 1438篇 |
免费 | 77篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 28篇 |
妇产科学 | 17篇 |
基础医学 | 136篇 |
口腔科学 | 4篇 |
临床医学 | 85篇 |
内科学 | 528篇 |
皮肤病学 | 82篇 |
神经病学 | 83篇 |
特种医学 | 28篇 |
外科学 | 164篇 |
综合类 | 7篇 |
预防医学 | 69篇 |
眼科学 | 8篇 |
药学 | 118篇 |
中国医学 | 8篇 |
肿瘤学 | 161篇 |
出版年
2023年 | 19篇 |
2022年 | 24篇 |
2021年 | 45篇 |
2020年 | 24篇 |
2019年 | 25篇 |
2018年 | 44篇 |
2017年 | 31篇 |
2016年 | 37篇 |
2015年 | 37篇 |
2014年 | 63篇 |
2013年 | 60篇 |
2012年 | 100篇 |
2011年 | 105篇 |
2010年 | 56篇 |
2009年 | 42篇 |
2008年 | 92篇 |
2007年 | 107篇 |
2006年 | 101篇 |
2005年 | 99篇 |
2004年 | 87篇 |
2003年 | 73篇 |
2002年 | 75篇 |
2001年 | 11篇 |
2000年 | 7篇 |
1999年 | 13篇 |
1998年 | 17篇 |
1997年 | 9篇 |
1996年 | 10篇 |
1995年 | 17篇 |
1994年 | 10篇 |
1993年 | 5篇 |
1992年 | 8篇 |
1991年 | 4篇 |
1990年 | 6篇 |
1989年 | 4篇 |
1988年 | 11篇 |
1987年 | 3篇 |
1985年 | 3篇 |
1984年 | 3篇 |
1983年 | 5篇 |
1982年 | 5篇 |
1981年 | 3篇 |
1980年 | 2篇 |
1979年 | 2篇 |
1978年 | 5篇 |
1977年 | 2篇 |
1976年 | 3篇 |
1975年 | 3篇 |
1971年 | 2篇 |
1968年 | 2篇 |
排序方式: 共有1530条查询结果,搜索用时 0 毫秒
991.
Yasuyuki Kamada Tomohide Hori Hidekazu Yamamoto Hideki Harada Michihiro Yamamoto Masahiro Yamada Takefumi Yazawa Ben Sasaki Masaki Tani Asahi Sato Hikotaro Katsura Ryotaro Tani Ryuhei Aoyama Yudai Sasaki Masaharu Okada Masazumi Zaima 《World journal of hepatology》2021,13(4):483-503
BACKGROUNDAlthough arterial hemorrhage after pancreaticoduodenectomy (PD) is not frequent, it is fatal. Arterial hemorrhage is caused by pseudoaneurysm rupture, and the gastroduodenal artery stump and hepatic artery (HA) are frequent culprit vessels. Diagnostic procedures and imaging modalities are associated with certain difficulties. Simultaneous accomplishment of complete hemostasis and HA flow preservation is difficult after PD. Although complete hemostasis may be obtained by endovascular treatment (EVT) or surgery, liver infarction caused by hepatic ischemia and/or liver abscesses caused by biliary ischemia may occur. We herein discuss therapeutic options for fatal arterial hemorrhage after PD.AIMTo present our data here along with a discussion of therapeutic strategies for fatal arterial hemorrhage after PD.METHODSWe retrospectively investigated 16 patients who developed arterial hemorrhage after PD. The patients’ clinical characteristics, diagnostic procedures, actual treatments [transcatheter arterial embolization (TAE), stent-graft placement, or surgery], clinical courses, and outcomes were evaluated.RESULTSThe frequency of arterial hemorrhage after PD was 5.5%. Pancreatic leakage was observed in 12 patients. The onset of hemorrhage occurred at a median of 18 d after PD. Sentinel bleeding was observed in five patients. The initial EVT procedures were stent-graft placement in seven patients, TAE in six patients, and combined therapy in two patients. The rate of technical success of the initial EVT was 75.0%, and additional EVTs were performed in four patients. Surgical approaches including arterioportal shunting were performed in eight patients. Liver infarction was observed in two patients after TAE. Two patients showed a poor outcome even after successful EVT. These four patients with poor clinical courses and outcomes had a poor clinical condition before EVT. Fourteen patients were successfully treated.CONCLUSIONTranscatheter placement of a covered stent may be useful for simultaneous accomplishment of complete hemostasis and HA flow preservation. 相似文献
992.
993.
994.
Mizuno Y Yasue H Yoshimura M Fujii H Yamamoto N Nakayama M Harada E Sakamoto T Nakamura S Ito T Shimasaki Y Ogawa H Saito Y Nakao K 《The American journal of cardiology》2002,89(10):1197-1200
The present study was designed to examine whether the production of aldosterone from the heart is suppressed by angiotensin-converting enzyme (ACE) inhibition in patients with heart failure. Forty-one patients with left ventricular systolic dysfunction were randomly divided into either the perindopril group (n = 21, perindopril 4 mg/day) or the placebo group (n = 20). Plasma levels of aldosterone and ACE activity were measured in the anterior interventricular vein, coronary sinus, and aortic root during cardiac catheterization. The levels of aldosterone as well as ACE activity were significantly higher at the anterior interventricular vein and the coronary sinus than at the aortic root in the placebo group (aldosterone: 92.1 +/- 9.0 vs 70.6 +/- 8.3 pg/ml [p <0.001]; 90.3 +/- 9.2 vs 70.6 +/- 8.3 pg/ml [p <0.001], respectively; ACE activity: 13.6 +/- 0.8 vs 12.2 +/- 0.7 IU/L [p <0.001], 13.4 +/- 0.8 vs 12.2 +/- 0.7 IU/L [p <0.001], respectively). On the other hand, there were no differences in the levels of aldosterone or ACE activity between the anterior interventricular vein and aortic root or between the coronary sinus and aortic root (aldosterone: 68.1 +/- 8.4 vs 69.9 +/- 9.4 pg/ml [p = NS]; 67.3 +/- 8.9 vs 69.9 +/- 9.4 pg/ml [p = NS], respectively; ACE activity: 9.7 +/- 0.8 vs 9.9 +/- 0.8 IU/L [p = NS]; 9.8 +/- 0.8 vs 9.9 +/- 0.8 IU/L, respectively) in the perindopril group. The levels of aldosterone as well as ACE activity were significantly lower at the anterior interventricular vein and coronary sinus in the perindopril group than in the placebo group. The difference in the level of aldosterone between the anterior interventricular vein and aortic root (Delta aldosterone [anterior interventricular vein - aortic root]) had a significant positive correlation with that of ACE activity (Delta ACE [anterior interventricular vein - aortic root]) (r = 0.536, p <0.001), whereas ACE activity in the aortic root had no significant correlation with either the aldosterone levels in the aortic root or Delta aldosterone (anterior interventricular vein - aortic root). Perindopril suppressed cardiac aldosterone production by mainly suppressing cardiac ACE activity in patients with heart failure. Thus, aldosterone production is activated in the failing ventricle and is suppressed by perindopril mainly via the suppression of cardiac ACE activity in patients with heart failure. 相似文献
995.
996.
997.
998.
Kanda Y Matsuda M Tawaramoto K Kawasaki F Hashiramoto M Matsuki M Kaku K 《Diabetes research and clinical practice》2008,81(1):13-18
Adiponectin is a fat-derived cytokine with anti-diabetic and anti-atherogenic properties. In this study, effects of sulfonylureas (SUs) on adiponectin production and the action mechanism were evaluated using 3T3-L1 adipocytes. The cells were incubated with glimepiride, glibenclamide, gliclazide, pioglitazone, metformin and the medium only as the control. In the control, the adiponectin level evaluated as the production rate per 24 h was not changed, while pioglitazone significantly increased the adiponectin level. SUs also increased the adiponectin level, but metformin failed to show any increase in adiponectin production. SUs induced adiponectin gene expression as well as pioglitazone. Pioglitazone significantly increased adipogenesis, but glimepiride did not. The aP2 gene expression was increased by pioglitazone, but not by glimepiride. Forskolin, a protein kinase A stimulator, reduced the adiponectin production stimulated by glimepiride but not by pioglitazone. These observations strongly suggest that SUs stimulate the adiponectin production through a different mechanism from pioglitazone, namely an interaction with protein kinase A activity. The significance of the extrapancreatic action of SUs observed in this study should be further evaluated in the clinical field. 相似文献
999.
Makoto Yoshimitsu Ryuji Tanosaki Koji Kato Takashi Ishida Ilseung Choi Yoshifusa Takatsuka Takahiro Fukuda Tetsuya Eto Michihiro Hidaka Naoyuki Uchida Toshihiro Miyamoto Yasuhiro Nakashima Yukiyoshi Moriuchi Koji Nagafuji Yasuhiko Miyazaki Tatsuo Ichinohe Minoko Takanashi Yoshiko Atsuta Atae Utsunomiya 《Biology of blood and marrow transplantation》2018,24(4):832-839
Disease status at allogeneic hematopoietic cell transplantation (HCT) is an important pretransplant prognostic factor of HCT in adult T cell leukemia/lymphoma (ATL); however, other prognostic factors, including comorbidities, were not predictive in small cohort analyses. Several scoring systems (HCT-specific comorbidity index [HCT-CI]/modified European Group for Blood and Marrow Transplantation risk score [mEBMT]) have been adopted to predict HCT outcomes in other hematologic malignancies. We retrospectively evaluated HCT-CI and mEBMT to predict nonrelapse mortality (NRM) in 824 ATL patients registered in the Japan Society for Hematopoietic Cell Transplantation TRUMP database, from 2008 until 2013. A higher HCT-CI was associated with greater NRM when comparing HCT-CI 0 versus HCT-CI 1 to 3 and HCT-CI 0 versus HCT-CI ≥ 4. A higher mEBMT score was not associated with higher NRM when comparing mEBMT 0 to 3 with 4 to 6. Because ATL patients are older and consequently at risk of additional complications, we developed an optimized prognostic index for ATL (ATL-HCT-PI) using known risk factors: age, HCT-CI, and donor–recipient sex combination. The ATL-HCT-PI scores effectively predicted the 2-year NRM (22.0%, 27.7%, and 44.4%, respectively). Therefore, the newly developed ATL-HCT-PI, in combination with other risk factors, is more useful for predicting NRM in HCT for ATL patients. 相似文献